BAYESIAN APPROACH TO NONINFERIORITY TRIALS FOR PROPORTIONS

被引:22
作者
Gamalo, Mark A. [1 ]
Wu, Rui [2 ]
Tiwari, Ram C. [1 ]
机构
[1] US FDA, Off Biostat, Silver Spring, MD 20993 USA
[2] Univ Connecticut, Dept Stat, Storrs, CT 06269 USA
关键词
Bayesian criterion; Bayesian paradigm; Beta-binomial; Noninferiority margin; Normal approximation; STATISTICAL-METHODS; PLACEBO; ISSUES;
D O I
10.1080/10543406.2011.589646
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Noninferiority trials are unique because they are dependent upon historical information in order to make meaningful interpretation of their results. Hence, a direct application of the Bayesian paradigm in sequential learning becomes apparently useful in the analysis. This paper describes a Bayesian procedure for testing noninferiority in two-arm studies with a binary primary endpoint that allows the incorporation of historical data on an active control via the use of informative priors. In particular, the posteriors of the response in historical trials are assumed as priors for its corresponding parameters in the current trial, where that treatment serves as the active control. The Bayesian procedure includes a fully Bayesian method and two normal approximation methods on the prior and/or on the posterior distributions. Then a common Bayesian decision criterion is used but with two prespecified cutoff levels, one for the approximation methods and the other for the fully Bayesian method, to determine whether the experimental treatment is noninferior to the active control. This criterion is evaluated and compared with the frequentist method using simulation studies in keeping with regulatory framework that new methods must protect type I error and arrive at a similar conclusion with existing standard strategies. Results show that both methods arrive at comparable conclusions of noninferiority when applied to a modified real data set. The advantage of the proposed Bayesian approach lies in its ability to provide posterior probabilities for effect sizes of the experimental treatment over the active control.
引用
收藏
页码:902 / 919
页数:18
相关论文
共 50 条
  • [41] A Note on Partial Covariate-Adjustment and Design Considerations in Noninferiority Trials When Patient-Level Data are not Available
    Nie, Lei
    Soon, Guoxing
    Qi, Karen
    Chen, Yong
    Chu, Haitao
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2013, 23 (05) : 1042 - 1053
  • [42] A valid formulation of the analysis of noninferiority trials under random effects meta-analysis
    Brittain, Erica H.
    Fay, Michael P.
    Follmann, Dean A.
    BIOSTATISTICS, 2012, 13 (04) : 637 - 649
  • [43] Approaches for testing noninferiority in two-arm trials for risk ratio and odds ratio
    Chowdhury, Shrabanti
    Tiwari, Ram C.
    Ghosh, Samiran
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2019, 29 (03) : 425 - 445
  • [44] BAYESIAN CREDIBILITY LIMITS FOR SMALL FINITE POPULATION PROPORTIONS - STRATIFIED AND CLUSTER SAMPLING
    GROSS, ST
    COMMUNICATIONS IN STATISTICS-THEORY AND METHODS, 1991, 20 (03) : 1027 - 1037
  • [45] Bayesian analysis of a 22 contingency table with dependent proportions and exact sample size
    Pham-Gia, T.
    Turkkan, N.
    STATISTICS, 2008, 42 (02) : 127 - 147
  • [46] Sample Size Requirements for Calibrated Approximate Credible Intervals for Proportions in Clinical Trials
    De Santis, Fulvio
    Gubbiotti, Stefania
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2021, 18 (02) : 1 - 11
  • [47] Bayesian Approach for Assessing Non-Inferiority in Three-Arm Trials for Risk Ratio and Odds Ratio
    Chowdhury, Shrabanti
    Tiwari, Ram C.
    Ghosh, Samiran
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2019, 11 (01): : 34 - 43
  • [48] Sample size calculations for noninferiority trials for time-to-event data using the concept of proportional time
    Phadnis, Milind A.
    Mayo, Matthew S.
    JOURNAL OF APPLIED STATISTICS, 2021, 48 (06) : 1009 - 1032
  • [49] Sample Size Calculation for "Gold-Standard" Noninferiority Trials With Fixed Margins and Negative Binomial Endpoints
    Homma, Gosuke
    Daimon, Takashi
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2021, 13 (04): : 435 - 447
  • [50] A Simulation Study Evaluating Bio-Creep Risk in Serial Noninferiority Clinical Trials for Preservation of Effect
    Odem-Davis, K.
    Fleming, T. R.
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2015, 7 (01): : 12 - 24